Sandoz reported on Monday the availability of Glatopa (glatiramer acetate injection) in 40 mg/ml for the treatment of relapsing forms of multiple sclerosis (MS).
The company said Glatopa (glatiramer acetate injection) 40 mg/ml is US FDA-approved as a fully-substitutable, AP-rated generic version of Copaxone (glatiramer acetate injection) 40 mg/ml three times-a-week therapy for relapsing forms of multiple sclerosis (MS).
According to the company Glatopa was developed under a collaboration agreement with Momenta Pharmaceuticals Inc and is produced in the US.
In conjunction, Glatopa 40 mg/ml, along with Glatopa 20 mg/ml, will offer patients a complete range of dosing options. Glatopa 20 mg/ml was made available in the US in June 2015. Patients can expect the same patient services for Glatopa 40 mg/ml as for Glatopa 20 mg/ml.
Additionally, Sandoz GlatopaCare will offer a USD0 co-pay support programme to qualified patients, personalized injection training as well as 24-hour access to nurses and a free Starter Kit, which includes the Glatopaject injection device designed to work with both Glatopa 20 mg/ml and 40 mg/ml prefilled syringes.
Headquartered in Holzkirchen, Greater Munich area, Germany, Sandoz is a generic pharmaceuticals and biosimilars company and a division of the Novartis.
TELA Bio launches LIQUIFIX for US hernia surgery
Cognizant and NVIDIA partner to revolutionize drug discovery with generative AI
Neupulse raises funds for Tourettes Syndrome wearable tech
Bonesupport gains FDA clearance for CERAMENT G in open fractures
Epitomee submits Weight Loss Capsule for FDA approval in US
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon